![]() ![]() Michael Cox will play a crucial role in driving the company's clinical development mission, providing strategic leadership, and overseeing the execution of early-stage clinical programs. With the leadership and expertise of Michael and Edward, the company is well-positioned to bring its transformative macrocycle therapeutics to patients.”ĭr. “We are in a period of dynamic growth as we prepare to advance our Cyclin A/B inhibitor into clinical studies. We look forward to their contributions as we advance our lead program into the clinic and continue to drive innovation in cancer treatment,” said David Earp, president and CEO of Circle Pharma. Their exceptional backgrounds and deep expertise in clinical development and medical affairs will be instrumental in accelerating our efforts to develop groundbreaking oncology therapeutics. “We are thrilled to welcome Michael and Edward to Circle Pharma. ![]() ![]() These additions to the leadership team further bolster Circle Pharma's capabilities in oncology drug development as it advances its Cyclin A/B inhibitor program into clinical studies. SAN FRANCISCO-( BUSINESS WIRE)-Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and Edward Garmey, M.D., as its new consulting chief medical officer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |